Julia Gamache

Julia Gamache

Auto-generated profile, based on publicly available information

Julia Gamache

Medtronic Neuromodulation , Minneapolis, MN

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJulia Gamache
Julia Gamache
KBKellie Benzow
Kellie Benzow
CFColleen Forster
Colleen Forster
LKLisa Kemper
Lisa Kemper
CHChris Hlynialuk
Chris Hlynialuk
MKMichael D. Koob
Michael D. Koob
The tauopathy-like phenotype observed in the rTg4510 mouse line, in which human tauP301L expression specifically within the forebrain can be temporally controlled, has largely been attributed to high overexpression of mutant human tau in the forebrain region. Unexpectedly, we found that in a different mouse line with a targeted-insertion of the same transgene driven by the same tetracycline-TransActivator (tTA) allele, but with even higher overexpression of tauP301L than rTg4510, atrophy and tau histopathology are delayed, and a different behavioral profile is observed. This suggests that it is not overexpression of mutant human tau alone that contributes to the phenotype in rTg4510 mice. Furthermore we show that the tauopathy-like phenotype seen in rTg4510 requires a ~70-copy tau-transgene insertion in a 244 kb deletion in Fgf14, a ~7-copy tTA-transgene insertion in a 508 kb deletion that disrupts another five genes, in addition to high transgene overexpression. We propose that these additional effects need to be accounted for in any studies using rTg4510.

1 August 2020 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
JGJulia Gamache
Julia Gamache
YYYoung Yun
Young Yun
Ornit Chiba-FalekOrnit Chiba-Falek
Ornit Chiba-Falek
The importance of apolipoprotein E (APOE) in late-onset Alzheimer9s disease (LOAD) has been firmly established, but the mechanisms through which it exerts its pathogenic effects remain elusive. In addition, the sex-dependent effects of APOE on LOAD risk and endophenotypes have yet to be explained. In this Review, we revisit the different aspects of APOE involvement in neurodegeneration and neurological diseases, with particular attention to sex differences in the contribution of APOE to LOAD susceptibility. We discuss the role of APOE in a broader range of age-related neurodegenerative diseases, and summarize the biological factors linking APOE to sex hormones, drawing on supportive findings from rodent models to identify major mechanistic themes underlying the exacerbation of LOAD-associated neurodegeneration and pathology in the female brain. Additionally, we list sex-by-genotype interactions identified across neurodegenerative diseases, proposing APOE variants as a shared etiology for sex differences in the manifestation of these diseases. Finally, we present recent advancements in ‘omics’ technologies, which provide a new platform for more in-depth investigations of how dysregulation of this gene affects the development and progression of neurodegenerative diseases. Collectively, the evidence summarized in this Review highlights the interplay between APOE and sex as a key factor in the etiology of LOAD and other age-related neurodegenerative diseases. We emphasize the importance of careful examination of sex as a contributing factor in studying the underpinning genetics of neurodegenerative diseases in general, but particularly for LOAD.

4 November 2019 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JGJulia E. Gamache
Julia E. Gamache
LKLisa Kemper
Lisa Kemper
ESElizabeth Steuer
Elizabeth Steuer
KLKailee Leinonen-Wright
Kailee Leinonen-Wright
JCJessica M. Choquette
Jessica M. Choquette
KAKaren H. Ashe
Karen H. Ashe
Tau is a microtubule-associated protein that becomes dysregulated in a group of neurodegenerative diseases called tauopathies. Differential tau isoforms, expression levels, promoters, and disruption of endogenous genes in transgenic mouse models of tauopathy make it difficult to draw definitive conclusions about the biological role of tau in these models. We addressed this shortcoming by characterizing the molecular and cognitive phenotypes associated with the pathogenic P301L tau mutation (rT2 mice) in relation to a genetically matched transgenic mouse overexpressing nonmutant (NM) 4-repeat (4R) human tau (rT1 mice). Both male and female mice were included in this study. Unexpectedly, we found that 4R NM human tau (hTau) exhibited abnormal dynamics in young mice that were lost with the P301L mutation, including elevated protein stability and hyperphosphorylation, which were associated with cognitive impairment in 5-month-old rT1 mice. Hyperphosphorylation of NM hTau was observed as early as 4 weeks of age, and transgene suppression for the first 4 or 12 weeks of life prevented abnormal molecular and cognitive phenotypes in rT1, demonstrating that NM hTau pathogenicity is specific to postnatal development. We also show that NM hTau exhibits stronger binding to microtubules than P301L hTau, and is associated with mitochondrial abnormalities. Overall, our genetically matched mice have revealed that 4R NM hTau overexpression is pathogenic in a manner distinct from classical aging-related tauopathy, underlining the importance of assaying the effects of transgenic disease-related proteins at appropriate stages in life.SIGNIFICANCE STATEMENTDue to differences in creation of transgenic lines, the pathological properties of the P301L mutation confers to the tau proteinin vivohave remained elusive, perhaps contributing to the lack of disease-modifying therapies for tauopathies. In an attempt to characterize P301L-specific effects on tau biology and cognition in novel genetically matched transgenic mouse models, we surprisingly found that nonmutant human tau has development-specific pathogenic properties of its own. Our findings indicate that overexpression of 4-repeat human tau during postnatal development is associated with excessive microtubule binding, which may disrupt important cellular processes, such as mitochondrial dynamics, leading to elevated stability and hyperphosphorylation of tau, and eventual cognitive impairments.

8 May 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ESElliot Keats Shwab
Elliot Keats Shwab
ZHAOHUI MANZHAOHUI MAN
ZHAOHUI MAN
DGDaniel C. Gingerich
Daniel C. Gingerich
JGJulia Gamache
Julia Gamache
MGMelanie E. Garrett
Melanie E. Garrett
Ornit Chiba-FalekOrnit Chiba-Falek
Ornit Chiba-Falek
INTRODUCTION: Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD) represent a spectrum of neurodegenerative diseases (NDDs). Here, we performed the first direct comparison of their transcriptomic landscapes.METHODS: We profiled whole transcriptomes of NDD cortical tissue by single‐nucleus RNA sequencing, using computational analyses to identify common and distinct differentially expressed genes (DEGs), pathways, vulnerable and disease‐driver cell subtypes, and altered cell‐to‐cell interactions.RESULTS: The same inhibitory neuron subtype was depleted in both AD and DLB. Potentially disease‐driving neuronal cell subtypes were identified in both PD and DLB. Cell–cell communication was predicted to be increased in AD but decreased in DLB and PD. DEGs were most commonly shared across NDDs within inhibitory neuron subtypes. Overall, AD and PD showed greatest transcriptomic divergence, while DLB exhibited an intermediate signature.DISCUSSION: These results may help explain the clinicopathological spectrum of these NDDs and provide unique insights into shared and distinct molecular mechanisms underlying pathogenesis.Highlights: The same vulnerable inhibitory neuron subtype population was depleted in both Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). Potentially disease‐driving neuronal cell subtypes were discovered in both Parkinson's disease (PD) and DLB. Cell–cell communication was predicted to be increased in AD but decreased in DLB and PD. Differentially expressed genes were most commonly shared across neurodegenerative diseases in inhibitory neuron types. AD and PD had the greatest transcriptomic divergence, with DLB showing an intermediate signature.

18 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ESE. Keats Shwab
E. Keats Shwab
ZMZhaohui Man
Zhaohui Man
DGDaniel C. Gingerich
Daniel C. Gingerich
JGJulia Gamache
Julia Gamache
MGMelanie E. Garrett
Melanie E. Garrett
Ornit Chiba-FalekOrnit Chiba-Falek
Ornit Chiba-Falek
INTRODUCTION Alzheimer’s disease (AD), Dementia with Lewy bodies (DLB), and Parkinson’s disease (PD) represent a spectrum of neurodegenerative disorders (NDDs). Here, we performed the first direct comparison of their transcriptomic landscapes. METHODS We profiled the whole transcriptomes of NDD cortical tissue by snRNA-seq. We used computational analyses to identify common and distinct differentially expressed genes (DEGs), biological pathways, vulnerable and disease-driver cell subtypes, and alteration in cell-to-cell interactions. RESULTS The same vulnerable inhibitory neuron subtype was depleted in both AD and DLB. Potentially disease-driving neuronal cell subtypes were present in both PD and DLB. Cell-cell communication was predicted to be increased in AD but decreased in DLB and PD. DEGs were most commonly shared across NDDs within inhibitory neuron subtypes. Overall, we observed the greatest transcriptomic divergence between AD and PD, while DLB exhibited an intermediate transcriptomic signature. DISCUSSION These results help explain the clinicopathological spectrum of this group of NDDs and provide unique insights into the shared and distinct molecular mechanisms underlying the pathogenesis of NDDs.

9 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJulio Barrera
Julio Barrera
LSLingyun Song
Lingyun Song
ASAlexias Safi
Alexias Safi
YYYoung Yun
Young Yun
MGMelanie E. Garrett
Melanie E. Garrett
Ornit Chiba-FalekOrnit Chiba-Falek
Ornit Chiba-Falek
In the post-GWAS era, there is an unmet need to decode the underpinning genetic etiologies of late-onset Alzheimer’s disease (LOAD) and translate the associations to causation. Toward that goal, we conducted ATAC-seq profiling using neuronal nuclear protein (NeuN) sorted-nuclei from 40 frozen brain tissues to determine LOAD-specific changes in chromatin accessibility landscape in a cell-type specific manner. We identified 211 LOAD-specific differential chromatin accessibility sites in neuronal-nuclei, four of which overlapped with LOAD-GWAS regions (±100kb of SNP). While the non-neuronal nuclei did not show LOAD-specific differences, stratification by sex identified 842 LOAD-specific chromatin accessibility sites in females. Seven of these sex-dependent sites in the non-neuronal samples overlapped LOAD-GWAS regions including APOE . LOAD loci were functionally validated using single-nuclei RNA-seq datasets. In conclusion, using brain sorted-nuclei enabled the identification of sex-dependent cell type-specific LOAD alterations in chromatin structure. These findings enhance the interpretation of LOAD-GWAS discoveries, provide potential pathomechanisms, and suggest novel LOAD-loci. Furthermore, our results convey mechanistic insights into sex differences in LOAD risk and clinicopathology. GRAPHICAL